Overexpression of P-glycoprotein, encoded by the MDR1 (multidrug resistance 1) gene, is often responsible for multidrug resistance and chemotherapy failure in cancer. We have demonstrated that, in leukaemic cells, P-glycoprotein expression is regulated at the translational level. More recently, we have shown that in cells overexpressing P-glycoprotein, MDR1 mRNA does not aggregate into translationally silent stress granules. Importantly, this is not unique for MDR1, since other transcripts encoding transmembrane proteins, and which are thus translated at the endoplasmic reticulum, follow the same pattern. By using a series of chimaeric transcripts, we have demonstrated that transcript localization at the endoplasmic reticulum bypasses the signals dictating stress granule sequestration. Polysome profile analyses and protein synthesis experiments indicate that, upon stress withdrawal, endoplasmic-reticulum-bound transcripts resume translation faster than those at the cytosol, which have been sequestered into stress granules. This may represent a novel mechanism by which drug-resistant cells respond quickly to stress, helping them to survive the cytotoxic effect of chemotherapeutic drugs.
Importantly, repair of DNA interstrand cross-links has been demonstrated to be a mechanism of clinical resistance to melphalan (a nitrogen mustard) in multiple myeloma.
(iv) An important aspect of carcinogenesis is resistance to cell death, in particular apoptosis. Up-regulation of antiapoptotic proteins such as Bcl-2, Bcl-X L and the IAP (inhibitor of apoptosis) family and inactivating mutations in the pro-apoptotic proteins Bax, Bak and p53 have been described in several models of drug resistance, and the restoration of p53-mediated apoptosis in cancer cells has been sought for some time, so far without a clinical application.
(v) Drug resistance can also result from decreased activity/expression of the uptake transporters, or, alternatively, from enhanced efflux. Water-soluble drugs, such as cisplatin, nucleoside analogues and antifolates, cannot cross the plasma membrane unless they 'piggy-back' on to membrane transporters or enter through hydrophilic channels in the membrane. Hydrophobic drugs, such as doxorubicin, vinblastine or paclitaxel, enter the cell largely by diffusion across the membrane, although this process can also be enhanced by transport proteins. Many types of drug-resistant cells have increased drug efflux such that the intracellular drug concentration remains below cytotoxic levels. These cells often express one or several ABC (ATP-binding cassette) transporters. These membrane proteins, encoded by as many as 49 different genes in humans, transport a variety of substrates across the membrane against a concentration gradient with the energy provided by ATP hydrolysis [2] . The most studied, ABCB1 [MDR1 (multidrug resistance 1), P-glycoprotein], ABCC1 [MRP1 (multidrug resistanceassociated protein 1)], and ABCG2 [BCRP (breast cancerresistance protein)], have been associated with the term MDR (multidrug resistance) due to the variety of compounds that these proteins can transport across the membrane [3] .
It is now more than 30 years since the first of these transporters, P-glycoprotein, was implicated in cancer drug resistance (reviewed in [2] ). Since then, research has focused on understanding its structure-function relationship and the development of inhibitors of transport that could be used in the clinic [4] . After many years of effort in many laboratories around the world, a low-resolution crystal structure of P-glycoprotein in one of the conformations of its transport cycle has been reported [5] . The development of clinically relevant inhibitors has also been a frustrating process. There are many different possible reasons for the failure of Phase III clinical trials targeting P-glycoprotein, such as multifactorial mechanisms of resistance, toxicity of the inhibitors and unfavourable pharmacological interactions, as well as a poor clinical trial design [6] . Even in AML (acute myelogenous leukaemia), in which P-glycoprotein expression directly affects the outcome of chemotherapy, patients are not routinely phenotyped and current efforts to develop simple intercentre reproducible protocols to detect P-glycoprotein in AML blasts are being developed [7] . Other alternative approaches to target MDR could involve the development of agents interfering with one of several of the many regulatory steps in P-glycoprotein expression: transcription, mRNA turnover, translation, protein processing and turnover. Of these, only ecteinascidin 743, a natural product isolated from the marine organism Ecteinascidia turbinata that interferes with the activation of MDR1 via the stress-responsive enhanceosome complex [8] , is under trials (currently Phase II) in soft tissue sarcomas [9] .
Translational regulation of MDR1 and generation of drug-resistant cells P-glycoprotein regulation due to changes in the MDR1 mRNA stability [10] , protein turnover [11] or trafficking [12] have been suggested, but it is transcriptional regulation that has, until recently, been considered the key step accounting for the complex spatiotemporal pattern of expression in vivo [13] [14] [15] . It has also generally been assumed that up-regulation of MDR1 mRNA leads to an increase in P-glycoprotein. For example, cells from tissues expressing P-glycoprotein, such as those from colon or liver, up-regulate both MDR1 mRNA and P-glycoprotein following different stresses, and are consequently transiently resistant to certain drugs. However, we have found that in cells from tissues with absent or low P-glycoprotein expression, another level of regulation can occur. Chronic myeloid erythroleukaemic K562 cells do not express P-glycoprotein and are thus a good model to study the mechanisms governing the generation of drug-resistant cells. Short-term (1-3 days) exposure of naïve K562 cells to cytotoxic agents results in up-regulation of MDR1 mRNA steady-state levels, by increasing the stability of the otherwise short-lived transcript. However, this mRNA is not associated with translating polyribosomes, and P-glycoprotein is not synthesized [16] .
The availability of eIF (eukaryotic initiation factor) 4E to bind the mRNA cap is dictated by the phosphorylation status of a family of translational repressors, 4E-BPs (eIF4E-binding proteins). 4E-BPs bind to eIF4E, thereby preventing its interaction with eIF4G (another initiation factor crucial for the formation of the initiation complex) and so inhibiting translation. Phosphorylation of 4E-BP molecules releases the 4E-BPs from eIF4E, which allows the interaction with eIF4G, and thereby allows translation to proceed. Importantly, phosphorylation of 4E-BPs is controlled by the PI3K (phosphoinositide 3-kinase)/Akt/mTOR (mammalian target of rapamycin) signalling pathway, which also plays a fundamental role in malignant transformation and proliferation [17] . As is well established in other cell systems, cytotoxic drugs down-regulate the Akt signalling pathway, leading to hypophosphorylation of the translational repressor 4E-BP and decreased eIF4E availability also in K562 cells [18] .
Importantly, RNase mapping indicates that the 5 -end of MDR1 mRNA adopts a highly structured fold [19] . Fusion of this structured 5 -region upstream of a reporter gene impedes its efficient translation, specifically under cytotoxic stress, by reducing its competitive ability for the translational machinery. The effect of cytotoxic stress can be mimicked in vivo by blocking the phosphorylation of 4E-BP by mTOR using rapamycin or eIF4E siRNA (short interfering RNA) and relieved by overexpression of either eIF4E or constitutively active Akt [18] .
However, in a small proportion of cells (approx. 5 per million) MDR1 mRNA competes successfully for the reduced amounts of eIF4E and translates small amounts of P-glycoprotein. Consequent drug efflux lowers the cytotoxic effect, and restoration of eIF4E availability results in a feedforward relief from stress-induced translational repression and to the acquisition of drug resistance. In these drugresistant cells, which have significantly up-regulated MDR1 mRNA levels, MDR1 mRNA associates with polysomes and P-glycoprotein is expressed. Whether this small population of cells that will become drug-resistant is pre-existing or is stochastically generated by the drug treatment is currently unknown, but the presence of a small side population of cells within many common cells lines showing stem-celllike properties has been reported [20] and certainly warrants further investigation.
Translational regulation represents a general regulatory step in P-glycoprotein expression since the phenomenon described above is not unique to K562 cells. Translational repression of MDR1 mRNA has also been described in EBV (Epstein-Barr virus)-transformed human B-lymphocytes [16] and in leukaemic CEM cells [21] . In addition, in leukaemia, there is a well-documented lack of correlation between MDR1 mRNA and P-glycoprotein levels [22] , and approx. 16% of AML patients are MDR1 mRNApositive, but P-glycoprotein-negative (M. Pallis, personal communication).
These findings have profound clinical implications. Since eIF4E is frequently overexpressed in human cancers, targeting eIF4E has been suggested as a way to repress Arsenite-treated cells were processed for combined immunofluorescence (SG) and subsequent RNA FISH (fluorescence in situ hybridization) to detect specific transcripts (black dots). Aggregation of a high proportion of cytosolic RNAs in SGs (white circles) was observed. However, there was a complete lack of co-localization between ER-associated transcripts and SGs. Polysome profile analyses indicate that all of the ER-bound mRNAs remain in sucrose gradient fractions corresponding to polysomes, whereas, in cytosolic RNAs, a significant proportion becomes ribosome-free. Upon stress, cytosolic mRNAs are sensitive to puromycin, whereas those that are ER-bound respond poorly to the translational inhibitor. After arsenite withdrawal, translation resumes more rapidly in the ER-bound than in the cytosol mRNAs. Figure based on data taken from [40] .
the translation of poorly competitive transcripts whose expression is involved in cancer progression such as cmyc, vascular endothelial growth factor and survivin, but without affecting the translation of housekeeping genes which have highly competitive mRNAs [23] . In experimental cell systems, targeting eIF4E by RNA interference suppresses cell growth, induces apoptosis and enhances chemotherapy response [24, 25] . However, from the clinical point of view, most efforts are being concentrated in the small molecule ribavirin, a physical mimic of the 7-methylguanosine mRNA cap, which has shown promising effects in cell systems [26] and proof-of-principle clinical trials in AML [27] . At millimolar concentrations, ribavirin interferes with guanosine and adenosine metabolism affecting viral replication and is currently used as an antiviral agent. However, its effects on eIF4E are noticeable at micromolar concentrations in cell systems, with the advantage that this concentration is readily available in patients and is not associated with significant toxicity.
Translational regulation of MDR1 in drug-resistant cells: escape from SG (stress granule) sequestration
In addition to cancerous tissue, P-glycoprotein is also naturally expressed at high levels in a number of healthy tissues, such as liver, kidney, colon and the endothelial blood-brain barrier. This expression pattern suggests that the physiological role of P-glycoprotein is that of a 'frontline' cellular defender against hydrophobic endo-and xenobiotics. As a consequence, P-glycoprotein is an important modulator of the biodistribution and pharmacokinetics of many non-chemotherapeutic drugs [28] . In the clinic, chemotherapeutic treatment is administered in cycles which can affect the dynamics of P-glycoprotein synthesis and ultimately influence the efficacy of the therapy. How then do P-glycoprotein-expressing cells respond to stress?
Eukaryotic cells respond to stress by selectively shutting down the translation of constitutively expressed genes, while simultaneously maintaining or enhancing the translation of specific stress-induced transcripts. This stress-induced translational shutdown is mediated by several cellular kinases, which phosphorylate the α-subunit of eIF2. eIF2α is a critical regulatory component of the ternary complex (formed by eIF2-bound Met-tRNA i Met and GTP) which is required for translation of all mRNAs [17, 29] . When translation is initiated in the absence of eIF2-GTP-Met-tRNA i Met , an eIF2/eIF5-deficient stalled 48S* pre-initiation complex is assembled. This stalled complex, together with its associated mRNA, assembles with other nuclear binding proteins that shuttle to the cytoplasm [such as TIA-1 (T-cell-restricted intracellular antigen-1) and TIAR (TIA-1-related protein)] where they aggregate in macromolecular structures called SGs [30] [31] [32] . Aggregation of many transcripts into SGs is dependent on the binding of TIA-1 to a loosely defined 37 nt element within the UTRs (untranslated regions) [33] . TIA-1 has a major role in SG formation since a TIA-1 truncation mutant lacking its RNA-binding domain prevents the arsenite-induced assembly of SGs [34] . SGs are found in somatic cells that have been exposed to a variety of stresses and have been observed to occur in subcutaneous tumour cells in mice following whole-animal radiotherapy [35] . Thus SGs are an integral part of the organism's response to stress and contain translationally repressed mRNAs.
The protein components of SGs are relatively well known [36] ; however, the same cannot be said for the identities of the mRNA components. In pioneer studies, oligo(dT) probes were used to detect the total pool of mRNAs in TIA-1-containing SGs [37] , whereas, in subsequent studies, ectopically expressed mRNAs from transiently transfected gene fusions under the transcriptional control of powerful promoters were used [38, 39] . However, detection of poly(A) mRNA as a whole is biased towards the most abundant transcripts and may not reflect the localization of specific subsets of mRNAs [i.e. less abundant transcripts or those whose abundance changes in response to specific stimuli, or those bound to the ER (endoplasmic reticulum)]. Similarly, the exogenously overexpressed chimaeric mRNAs generated by transiently transfected plasmids may not be accurate surrogates for endogenous transcripts for the study of these processes under physiological conditions.
For these reasons, we decided to study the spatiotemporal localization of endogenous MDR1 transcripts in drugresistant cells upon stress. As have others, we found that a standard treatment of 45 min with 1 mM sodium arsenite triggered a dramatic reduction in protein synthesis, phosphorylation of eIF2α and approx. 50% of poly(A) and ACTB (β-actin) transcript signals co-localizing with SGs [40] . Unexpectedly, MDR1 mRNA does not co-localize with SGs upon stress and shows the same punctate pattern as that obtained in unstressed cells. Sucrose gradient fractionation to detect polyribosome loading indicates that only cytosolic transcripts, such as ACTB, H3.3 (histone 3.3) or RPS6 (ribosomal protein S6) lose ribosomes completely, migrating in the very-light sucrose fractions. However, transcripts coding for transmembrane proteins and which are thus ERbound, such as MDR1, EGFR (epidermal growth factor receptor) or CANX (calnexin) maintain their migration in sucrose gradients at densities corresponding to those of polyribosomes. This different migration in polysome gradients could not be explained by IRESs (internal ribosome entry sites) that would allow translation during stress, since exhaustive experiments using mono-and bi-cistronic luciferase reporter constructs [41] have ruled out the presence of an IRES in MDR1 mRNA. Thus there is a differential dynamics of transcripts upon stress: those located in the cytosol aggregate into SG, whereas those at the ER escape SG sequestration (Figure 1) .
Is there any hierarchy in the RNA elements determining the fate with regard to SGs? By using a series of chimaeric luciferase constructs carrying several regions of the MDR1 mRNA 5 -end, it is clear that a TIA-1-binding element must exist in its 5 -UTR, since these chimaeric transcripts, which locate at the cytosol, aggregate into SGs upon stress. However, when these transcripts are tethered to the ER, by introduction of the MDR1-coding sequences responsible for P-glycoprotein membrane integration, they escape sequestration into SGs upon stress [40] (Figure 2 ). Although these experiments need to be reconfirmed using different signal sequences and chimaeras to allow us to generalize, a pattern is emerging in which ER localization overcomes SG sequestration.
What is the fate of transcripts upon stress withdrawal? The pioneering work on SGs by Nancy Kedersha and Paul Anderson [31] offers a mechanistic view of the fate of RNA during stress: RNAs sequestered into SGs would be protected from degradation and, in addition, SGs would represent sites of triage upon stress withdrawal where RNAs could be targeted to degradation, storage or marked for translational reinitiation. However, the fate of transcripts following their release from SGs is not very well understood. We propose that the location of transcripts at the ER represents a similar mechanism for RNA protection [40] . In fact, MDR1 mRNA recovers its translational profile in sucrose gradients much faster than a cytosolic transcript, such as ACTB. Further confirmation using chimaeric MDR1-luciferase transcripts indicates that, upon stress withdrawal, those located at the ER resume translation ([ 35 S]methionine incorporation) faster than those at the cytosol, which have aggregated into SGs [40] . In a similar way, the stalling of translating ribosomes during mitosis has been discussed as a way of protecting mRNAs and allowing rapid resumption of translation immediately upon entry into the G 1 -phase [42] .
An important issue which will require further investigation is whether ER-bound transcripts remain physically associated with ribosomes or transiently become part of another macromolecular complex during stress. Importantly, we have demonstrated that they remain associated with the ER, while becoming puromycin-insensitive [40] . Puromycin inhibits the peptidyltransferase activity of the translating ribosome by causing chain termination when it is incorporated into the nascent polypeptide chain. Therefore addition of puromycin causes actively translating transcripts to move to lighter sucrose density fractions as ribosomes drop off the transcript. Following cytotoxic stress, a proportion of cytosolic transcripts completely disengages from ribosomes while the rest remains bound to ribosomes, probably due to the dual partitioning model proposed by Nicchitta et al. [43] , by which all transcripts, irrespective of their final location, spend part of their life cycle associated with the ER. Conversely, ER-bound transcripts respond very poorly to puromycin during stress. In a different context, pseudo-polysomes, with characteristics similar to those described by us for ER-bound transcripts during stress (puromycin resistance, EDTAsensitivity, migration in heavy sucrose gradient fractions), have already been described [44] , although, to our knowledge, no further characterization has been reported. These findings would argue in favour of an association of ER-bound transcripts with an as yet unidentified high-molecularmass ribonucleoprotein complex during stress. However, the presence of RPLP0 (ribosomal protein, large P0), a protein component of the large ribosomal subunit, in sucrose gradient fractions corresponding to those in which ERbound transcripts migrate during stress, and the translation ([ 35 S]methionine incorporation) of ER-resident chimaeric MDR1-luciferase mRNA, argue in favour of slowed or impaired elongation of ER-bound polyribosomes following cytotoxic stress compared with the stronger translational inhibition observed for cytosol-resident transcripts. In fact, the ER as a privileged site of translation has been suggested before by Nichitta's group, since inhibition of cap-dependent translation by Coxsackie B virus [45] or eliciting the unfolded protein response [46] results in suppression of mRNA translation in the cytosol, but sustained, albeit reduced, translation in the ER compartment.
Irrespective of the molecular fate of ER-resident transcripts during stress discussed above, we [40] and others [43] have demonstrated that cytosolic and ER-associated transcripts respond differently to the inhibition of translation following cellular stress. The rapid response we identify in restoring MDR1 translation upon removal of stress must be instrumental in its role in restoring cell homoeostasis, and may represent another way envisaged by cancer cells to survive the cytotoxic effect of chemotherapeutic treatment.
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